Innospec Inc. (IOSP) Market Cap & Valuation Ratios
Innospec Inc. (IOSP) has a market cap of $2.4B, a trailing P/E of 20.1 and a price-to-sales ratio of 1.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IOSPInnospec Inc.Follow IOSP — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- 20.1
- Dividend yield
- 1.8%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Peers
specialty chemicals · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| IOSP | 2.4 | 20.1 | 1.2 | 12.8 | 2.0% | +3% | 7% | 10% |
| CBT | 3.8 | 20.7 | 1.3 | 7.2 | 7.4% | -5% | 14% | 10% |
| AVNT | 3.8 | 22.2 | 1.6 | 10.3 | 5.1% | +2% | 9% | 6% |
| ASH | 3.3 | 69.5 | 2.3 | 13.0 | 7.5% | -1% | 7% | 3% |
| WDFC | 2.9 | 32.3 | 4.3 | 22.6 | 2.8% | +10% | 17% | 29% |
| HWKN | 2.8 | 34.3 | 2.7 | 17.3 | 3.3% | +9% | 11% | 12% |
| KWR | 2.7 | 27.8 | 1.7 | 13.5 | 2.8% | +8% | 8% | 5% |
| FUL | 2.7 | 13.8 | 1.3 | 7.9 | 3.7% | +1% | 11% | 7% |
| NGVT | 2.4 | 46.4 | 3.0 | 6.7 | 6.5% | -1% | 36% | 29% |
| MTX | 2.0 | — | 1.2 | 39.4 | 6.1% | +4% | -1% | -1% |
| CC | 1.9 | — | 0.9 | 9.5 | 11.3% | -0.9% | 4% | 5% |
| Median of these 10 | 30.1 | 1.6 | 11.7 | 5.6% | +2% | 10% | 7% |
P/E 20.1 vs. a peer median of 30.1; EV/Sales 1.2 vs. 1.6. IOSP's own P/E sits at the 37th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesMTX and CC have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Innospec Inc. — questions
- What is Innospec Inc.'s market cap?
- $2.4B.
- What is Innospec Inc.'s P/E ratio?
- 20.1 on trailing twelve-month earnings to 2026-06-30.
- What is Innospec Inc.'s price-to-sales ratio?
- 1.3.
Every figure on this page comes from Innospec Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.